Treatment resistance in non-small cell lung cancer remains one of oncology's most stubborn problems, and mounting evidence points to the tumor's surrounding ecosystem—not just the cancer cell itself—as a central driver. Understanding how that ecosystem reorganizes under therapeutic pressure could redefine how clinicians sequence and combine therapies for the most common form of lung cancer.
This review, published in Seminars in Cancer Biology, examines how the tumor microenvironment (TME) in NSCLC evolves across space and time as it encounters targeted therapies, immunotherapies, and conventional chemotherapy. The TME is a densely interconnected system comprising cancer-associated fibroblasts, tumor-infiltrating lymphocytes, myeloid-derived suppressor cells, endothelial cells, extracellular matrix scaffolding, and a suite of soluble signaling factors including cytokines and chemokines. The review synthesizes evidence showing that bidirectional crosstalk between malignant cells and these stromal components is not static—it shifts dynamically in response to each therapeutic intervention, often in ways that paradoxically shield residual tumor cells from subsequent treatment. Spatial heterogeneity within the tumor mass compounds this challenge, as immune-excluded and immune-desert regions can coexist with inflamed zones within the same lesion.
This conceptual framing matters because the dominant clinical narrative has focused on acquired genetic mutations—EGFR secondary mutations, MET amplification, histologic transformation—as the primary resistance mechanisms. The TME-centric view adds a non-cell-autonomous layer that genetic sequencing alone cannot capture. From a practical standpoint, this suggests that treatment strategies designed to simultaneously target tumor cells and reshape their microenvironment may outperform sequential monotherapies. However, as a narrative review rather than a meta-analysis or clinical trial, the paper synthesizes existing literature without generating new effect-size estimates. The field still lacks large prospective datasets linking longitudinal TME profiling to patient outcomes, which limits immediate clinical translation. This review is best characterized as a well-organized conceptual synthesis—valuable for framing future trial design rather than changing current practice.